The effect of a dopamine agonist on dysarthric speech production: a case study.
The effect of Permax (pergolide mesylate), a dopamine agonist, was assessed in an individual with traumatic brain injury. The participant evidenced symptoms of hypokinetic dysarthria. His performance on and off Permax was evaluated in a BABA design. Measures were obtained across physiological systems. There were few differences in the on and off conditions. In the on condition, he evidenced an abnormally large velopharyngeal orifice area, dysfluencies in stimulus sentences, and less precise articulation. However, listeners perceived him to be more animated in the on condition. In addition, he reported better performance in the on condition. The study highlights potential discrepancies among participant report, listener perception, and objective measures.


OBJECTIVE
As a result of this activity, the participant will be able (1) to recognize the effect of dopamine agonists as an adjunct to other pharmacological interventions and (2) to determine potential discrepancies among participant report, listener perception and objective physiological and acoustic measures.
McHenry
M
M
Transitional Learning Center, Department of Communication Disorders, University of Houston, TX 77204-6018, USA. mmchenry@uh.edu
D000328:Adult; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004401:Dysarthria / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010479:Pergolide / Q000627:therapeutic use*; D013064:Speech Disorders / Q000188:drug therapy*; D016896:Treatment Outcome
D018491:Dopamine Agonists; D010479:Pergolide